BVF Partners logo

BVF Partners

Crunchbase
Pitchbook
Crunchbase

Deals on record

9

Common Fundraising Type

Series A

Numab Therapeutics is a biotech company that develops multi-specific antibody-based immunotherapies for inflammation and cancer.

Series C
$55M
01/10/2025
Article
Ambrosia Biosciences logo
Ambrosia Biosciences

Drug discovery

Merck logo
BVF Partners logo
Boulder Ventures logo

Ambrosia Biosciences develops orally delivered, small molecule-based therapies for obesity and metabolic disorders.

Series A
$25M
12/11/2024
Article
Alpha-9 Oncology logo
Alpha-9 Oncology

Radiopharmaceuticals

Ascenta Capital logo
Lightspeed Venture Partners logo
Samsara BioCapital logo
RA Capital Management logo
Nextech Invest logo
Longitude Capital logo
General Catalyst logo
Digitalis Ventures logo

Alpha-9 Oncology Inc. develops targeted radiopharmaceuticals to improve cancer treatment.

Series C
$175M
10/23/2024
Article

Bambusa Therapeutics Inc. develops bispecific antibodies for treating immunological and inflammatory disorders.

Seed
$15M
09/09/2024
Article
Ambrosia Biosciences logo
Ambrosia Biosciences

Drug discovery

Boulder Ventures logo
BVF Partners logo

Ambrosia Biosciences develops orally delivered, small molecule-based therapies for obesity and metabolic disorders.

Series A
$16M
08/21/2024
Article
Lassen Therapeutics logo
Lassen Therapeutics

Clinical-stage biotech

Longitude Capital logo
Longwood Capital logo
Frazier Life Sciences logo
Catalio Capital Management logo
BVF Partners logo
Alta Partners logo

Lassen Therapeutics is a clinical-stage biotech company developing novel treatments for fibro-inflammatory diseases and cancer, focusing on therapies targeting the IL-11 and IL-18 pathways.

Series B
$85M
12/19/2023
Article
Aro Biotherapeutics logo
Aro Biotherapeutics

Biotechnology

Cowen Healthcare Investments logo
Johnson & Johnson Innovation logo
Northpond Ventures logo
Healthcap logo
BVF Partners logo

Aro Biotherapeutics is a clinical stage biotech company specializing in the development of tissue-targeted genetic medicines, including a potential treatment for Pompe Disease and new therapies for autoimmune disorders, using their proprietary Centyrin-siRNA platform.

Series B
$41.5M
11/28/2023
Article

Forward Therapeutics is a company focused on advancing the development of next-generation small molecule immune therapies.

Series A
$50M
11/08/2023
Article
Nimbus Therapeutics logo
Nimbus Therapeutics

Computational Drug Discovery

SR One logo
GV logo
Atlas Venture logo
SV Health Investors logo
RA Capital Management logo
Pfizer Ventures logo
Bain Capital Life Sciences logo
BVF Partners logo

Nimbus Therapeutics is a clinical-stage company that uses computational chemistry and structure-based drug design to develop novel therapies for immunology, cancer, and metabolic diseases.

Equity
$210M
09/06/2023
Article